Division of Vaccines and Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.
PLoS One. 2012;7(8):e43396. doi: 10.1371/journal.pone.0043396. Epub 2012 Aug 27.
The sieve analysis for the Step trial found evidence that breakthrough HIV-1 sequences for MRKAd5/HIV-1 Gag/Pol/Nef vaccine recipients were more divergent from the vaccine insert than placebo sequences in regions with predicted epitopes. We linked the viral sequence data with immune response and acute viral load data to explore mechanisms for and consequences of the observed sieve effect.
Ninety-one male participants (37 placebo and 54 vaccine recipients) were included; viral sequences were obtained at the time of HIV-1 diagnosis. T-cell responses were measured 4 weeks post-second vaccination and at the first or second week post-diagnosis. Acute viral load was obtained at RNA-positive and antibody-negative visits.
Vaccine recipients had a greater magnitude of post-infection CD8+ T cell response than placebo recipients (median 1.68% vs 1.18%; p = 0·04) and greater breadth of post-infection response (median 4.5 vs 2; p = 0·06). Viral sequences for vaccine recipients were marginally more divergent from the insert than placebo sequences in regions of Nef targeted by pre-infection immune responses (p = 0·04; Pol p = 0·13; Gag p = 0·89). Magnitude and breadth of pre-infection responses did not correlate with distance of the viral sequence to the insert (p>0·50). Acute log viral load trended lower in vaccine versus placebo recipients (estimated mean 4·7 vs 5·1) but the difference was not significant (p = 0·27). Neither was acute viral load associated with distance of the viral sequence to the insert (p>0·30).
Despite evidence of anamnestic responses, the sieve effect was not well explained by available measures of T-cell immunogenicity. Sequence divergence from the vaccine was not significantly associated with acute viral load. While point estimates suggested weak vaccine suppression of viral load, the result was not significant and more viral load data would be needed to detect suppression.
Step 试验的过筛分析发现,与安慰剂组序列相比,MRKAd5/HIV-1 Gag/Pol/Nef 疫苗接种者的突破性 HIV-1 序列在预测表位区域与疫苗插入序列的差异更大。我们将病毒序列数据与免疫反应和急性病毒载量数据相关联,以探索观察到的过筛效应的机制和后果。
纳入 91 名男性参与者(37 名安慰剂组和 54 名疫苗组);在 HIV-1 诊断时获得病毒序列。在第二次接种后 4 周和诊断后第一或第二周测量 T 细胞反应。在 RNA 阳性和抗体阴性就诊时获得急性病毒载量。
与安慰剂组相比,疫苗组感染者感染后 CD8+T 细胞反应的幅度更大(中位数 1.68%比 1.18%;p=0.04),感染后反应的广度更大(中位数 4.5 比 2;p=0.06)。疫苗组病毒序列与插入序列的差异在 Nef 靶向的区域比安慰剂组更接近插入序列,这一差异具有边缘统计学意义(针对感染前免疫反应的 Nef 靶向区域,p=0.04;针对 Pol 的 p=0.13;针对 Gag 的 p=0.89)。感染前反应的幅度和广度与病毒序列与插入序列的距离无关(p>0.50)。与安慰剂组相比,疫苗组急性病毒载量呈下降趋势(估计平均值 4.7 比 5.1),但差异无统计学意义(p=0.27)。病毒序列与插入序列的距离与急性病毒载量也无关(p>0.30)。
尽管有记忆反应的证据,但可用的 T 细胞免疫原性测量方法并不能很好地解释过筛效应。与疫苗的序列差异与急性病毒载量无显著关联。虽然点估计表明疫苗对病毒载量有微弱的抑制作用,但结果并不显著,需要更多的病毒载量数据来检测抑制作用。